DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked fifth in overall company reputation among patient groups who have worked directly with the company and seventh among patient groups who knew the company. The results are based on PatientView’s annual survey of 2,150 patient groups.
For the 2021 survey, 180 patient groups said they knew about Horizon, an increase of 46 from 2020. Additionally, 87 groups said they had worked with the company, an increase of 51 from 2020.
“At Horizon, being an advocate is personal because many employees are patients or caregivers,” said Matt Flesch, vice president, patient advocacy and communications. “In 2021, we were energized by meeting and supporting many new patient advocacy groups as Horizon expanded internationally and began working on several new disease states to support our growing pipeline. We are grateful for the feedback we received through the PatientView survey and strive to continue to actively engage new patient groups and support their efforts.
Report Highlights
The survey results were presented in two sets of rankings: one based on responses from groups who have worked directly with the company, the other from groups who are familiar with Horizon but have not worked with it. the company.
-
For both rankings, in each of the 13 indicators, Horizon ranked first among global pharmaceutical and biotechnology companies.
-
Of the patient groups that said they partnered with Horizon, the company ranked fifth overall; these groups ranked the company in the top five when asked about attributes such as patient focus, patient-group relationships, and high integrity.
-
Among patient groups that had not worked with the company, Horizon ranked seventh overall in terms of familiarity.
Horizon’s Commitment to Patients and Their Advocates
Horizon actively partners with patient advocacy organizations to raise awareness of many underrepresented diseases and advocate for the rights of patients and their communities. 2021 highlights included:
- Partnership with EveryLife Foundation to enrich patients through the #RAREest Scholarship, a $1 million commitment through 2025 to support the pursuit of life-enriching activities for adults (17 years and older) living with rare diseases for a variety of educational activities , including educational courses and the completion of two- and four-year degrees. To date, nearly 100 adults living with rare diseases have received $5,000 scholarships. Applications for Fall 2023 will open in Spring 2023.
- Amplified voices and support for sharing uncensored truths about rare diseases through the #RAREis program. Since its inception in 2017, over 300 photos, blogs and stories submitted by the rare disease community, covering over 70 different rare diseases, have been featured on the platform. Horizon also presented more than 30 #RAREis Voice videos of prominent advocates, patients and researchers sharing common experiences that many people living with rare diseases face.
- In partnership with the Jeffrey Modell Diagnostic and Research Center to support the expansion of two of their centres. The multi-pronged initiative aims to break down diagnostic barriers and increase awareness programs for those affected by primary immunodeficiency.
- Collaboration with over 100 patient groups to extend reach, increase engagement and develop educational opportunities for patients and their caregivers in live and virtual environments to elevate their stories, experiences and voices.
About Horizon
Horizon is focused on the discovery, development and commercialization of drugs that address the critical needs of people affected by rare, autoimmune and serious inflammatory diseases. Our pipeline is useful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on TwitterLinkedIn, Instagram and Facebook.
